European Journal of Cancer
Volume 45, Issue 1 , Pages 48-55 , January 2009

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

  • F. Caponigro

      Affiliations

    • Medical Oncology B, National Tumour Institute of Naples ‘Fondazione G. Pascale’ Via M. Semmola, 80131 Naples, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 081 5903362; fax: +39 081 5903822.
    • ,
  • D. Lacombe

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
    • ,
  • C. Twelves

      Affiliations

    • St. James’s Institute of Oncology, Leeds, United Kingdom
    • ,
  • J. Bauer

      Affiliations

    • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    • ,
  • A.-S. Govaerts

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
    • ,
  • S. Marréaud

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
    • ,
  • A. Milano

      Affiliations

    • Medical Oncology B, National Tumour Institute of Naples ‘Fondazione G. Pascale’ Via M. Semmola, 80131 Naples, Italy
    • ,
  • A. Anthoney

      Affiliations

    • St. James’s Institute of Oncology, Leeds, United Kingdom

Received 14 July 2008 ,Revised 4 August 2008 ,Accepted 6 August 2008.

  • Image Result

    Per patient CA19.9 as a percentage of baseline across 5 treatment cycles in responders versus non-responders.

    Per patient CA19.9 as a percentage of baseline across 5 treatment cycles in responders versus non-responders.

PII: S0959-8049(08)00640-0

doi: 10.1016/j.ejca.2008.08.011

European Journal of Cancer
Volume 45, Issue 1 , Pages 48-55 , January 2009

Article Tools

* Image Usage & Resolution